Adermykon
Adermykon Brand names, Adermykon Analogs
Adermykon Brand Names Mixture
- No information avaliable
Adermykon Chemical_Formula
C52H98N16O13
Adermykon RX_link
No information avaliable
Adermykon fda sheet
Adermykon msds (material safety sheet)
Adermykon Synthesis Reference
No information avaliable
Adermykon Molecular Weight
2797.3193 g/mol
Adermykon Melting Point
200 - 220 oC
Adermykon H2O Solubility
5.64E+005 mg/L
Adermykon State
Solid
Adermykon LogP
-4.648
Adermykon Dosage Forms
Capsule; Cream; Liquid; Ointment; Powder for solution; Solution; Suspension; Tablet; Tablet (enteric-coated); Tablet (extended-release)
Adermykon Indication
For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa.
Adermykon Pharmacology
Colistin is a polymyxin antibiotic agent. Polymyxins are cationic polypeptides that disrupt the bacterial cell membrane through a detergentlike mechanism. With the development of less toxic agents, such as extended-spectrum penicillins and cephalosporins, parenteral polymyxin use was largely abandoned, except for the treatment of multidrug-resistant pulmonary infections in patients with cystic fibrosis. More recently, however, the emergence of multidrug-resistant gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii, and the lack of new antimicrobial agents have led to the revived use of the polymyxins.
Adermykon Absorption
Very poor absorption from gastrointestinal tract.
Adermykon side effects and Toxicity
Oral LD50 in rats is 5450 mg/kg. Overdosage with colistimethate can cause neuromuscular blockade characterized by paresthesia, lethargy, confusion, dizziness, ataxia, nystagmus, disorders of speech and apnea. Respiratory muscle paralysis may lead to apnea, respiratory arrest and death.
Adermykon Patient Information
No information avaliable
Adermykon Organisms Affected
Gram-negative bacilli
